Bio-rad Laboratories, Inc. · NYSE:BIO
Bio-rad Laboratories — Bio-Rad's Droplet Digital PCR Webinar (August 2025)
18 slides from Bio-rad Laboratories's conference presentation, Aug 26, 2025
Slide 1: Droplet Digital PCR – Powering the Future
Droplet Digital PCR – Powering the Future Bio-Rad Laboratories, Inc. NYSE: BIO and BIO.B August 26, 2025
Slide 2: Safe Harbor
Safe Harbor Forward-Looking Statements. Some statements in this presentation and the related webinar and Q&A session may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals, p
Slide 3: Agenda
Agenda 01 Digital PCR Technology 03 Bio-Rad’s Digital PCR Portfolio 02 Segment Growth Drivers 04 Powering the Future of Digital PCR 3
Slide 4: The Evolution of PCR to Digital PCR
The Evolution of PCR to Digital PCR 1st Gen 2nd Gen 3rd Gen PCR qPCR dPCR Qualitative Relative Quantification Absolute Quantification Democratized the study of DNA Made PCR quantitative Absolute quantification of nucleic acids Revolutionized the study of Accelerated the biotech industry gene express
Slide 5: Bio-Rad's Innovation in Digital PCR
Bio-Rad’s Innovation in Digital PCR 2010 2025 Bio-Rad Bio-Rad Diagnostic Absolute Application Commercializes Continues to Registration Accuracy Expansion Digital PCR Lead the Way QX100 Droplet First FDA-Cleared First dPCR System to Novel digital PCR 12,000+ Peer- Digital PCR System and CE-IVD delive
Slide 6: Droplets are the Benchmark for Precision, Sensitivity, and Reproducibility
Droplets are the Benchmark for Precision, Sensitivity, and Reproducibility Our droplet-based approach delivers the highest quality data Droplets are highly uniform in size and volume, resulting in greater precision Droplets are highly reproducible in size and volume across instruments and labs Dropl
Slide 7: Droplets Enable Applications that Save Lives
Droplets Enable Applications that Save Lives Our droplet-based approach delivers the highest quality data Oncology Biopharma Production Bio-Surveillance Liquid biopsy requires Dose control requires Monitoring wastewater sensitivity accuracy requires reproducibility Monitoring requires precision Cont
Slide 8: Drivers of Absolute Quantitation Segment Growth are Evolving
Drivers of Absolute Quantitation Segment Growth are Evolving Expanding system use and consumables, plus rising demand for better precision and sensitivity Proven clinical utility drives dPCR into routine Increased adoption of diagnostics dPCR alongside qPCR/NGS for unmet needs Early adoption of dPCR
Slide 9: As Customer Needs Evolve, Solutions Must Advance
As Customer Needs Evolve, Solutions Must Advance Targeted Sequencing (NGS) Quantitative PCR (qPCR) Advantages: Challenges: Advantages: Challenges: • High Multiplexing • Lower sensitivity • Low cost • Lower sensitivity • Discovery Tool • Long time to result • Fast results • Variability of results • H
Slide 10: Droplet Digital PCR Meets Evolving Customer Needs
Droplet Digital PCR Meets Evolving Customer Needs Droplet Digital PCR Targeted Sequencing (NGS) Quantitative PCR (qPCR) High Sensitivity Fast More Challenges create Results Reproducible Challenges create opportunities for opportunities for ddPCR solutions ddPCR solutions Cost Absolute effective Meas
Slide 11: Bio-Rad Platforms Power the Entire Digital PCR Applications Without Compromise
Bio-Rad Platforms Power the Entire Digital PCR Applications Without Compromise Existing Bio-Rad QX Continuum QX700 Series Portfolio Platform Platform QX200 , QX600 , QX ONE and Simplest, qPCR-like workflow Integrated workflow with highest QXDx ddPCR platforms available multiplexing on the market Sup
Slide 12: Positioning of Bio-Rad ddPCR Platforms
Positioning of Bio-Rad ddPCR Platforms High Performance BioPharma QA/QC Academic / Translational QX600 QX700 S QX700 HT QX ONE Entry Level Clinical/LDT Labs Academic / Translational QX700 E QX Continuum QXDx QX600Dx 12
Slide 13: Our Industry Leading Assay Catalog Fuels Growth & Technology Conversion
Our Industry Leading Assay Catalog Fuels Growth & Technology Conversion Bio-Rad Maintains a catalog of over 490,000 assays for the research community High Value Powerful Design External Tests Algorithms Partnerships in oncology, cell & gene and expert design services to to expand the clinical assay
Slide 14: ~600,000 Assays Designed for qPCR and Compatible with ddPCR Systems
Our Industry Leading Assay Catalog - By the Numbers 34,000+ 12,500+ 445,000+ Validated Mutation Validated Copy Validated Gene Detection Assays Number Assays Expression Assays 50+ 60+ 50+ Infectious Validated Assays for Methylation Disease Assays Cell & Gene Therapy Detection Assays ~600,000 Assays D
Slide 15: Peer-Reviewed Publications Demonstrate Value of Bio-Rad's Droplet Digital PCR
Peer-Reviewed Publications Demonstrate Value of Bio-Rad’s Droplet Digital PCR2 Primary research articles continue to account for the majority of publications There is a strong shift from method development towards clinical applications 15
Slide 16: Powering the Future of Digital PCR
Powering the Future of Digital PCR Superior, Foundational Technology • Digital PCR technology and market innovator since 2010 • Droplet partitioning independently verified as providing “unprecedented” levels of analytical capability Digital PCR Expertise • Over 12,000 clinical and research publicati
Slide 17: Droplet Digital PCR - Powering the Future
Droplet Digital PCR - Powering the Future 17
Slide 18: Sources and Citations
Sources and Citations 1. Absolute Quantitation segment sizing based on Bio-Rad internal data comprised of primary and secondary research; July 2025. 2. Peer-reviewed primary research publications and review articles utilizing Bio-Rad Droplet Digital PCR Systems from 2012-2024. Bio-Rad internal data
Bio-Rad Laboratories — Bio-Rad's Droplet Digital PCR Webinar (August 2025) on 6ix